
By the time a clinical research site identifies a major screening bottleneck, site coordinators may have already spent hours evaluating patients who don’t meet the protocol. Screen failures pile up, the enrollment timeline starts to slip and patient recruitment costs climb. By then, the budget, the timeline and the clinical site network are already committed.
Some of these screening challenges can be identified before clinical research sites begin patient recruitment. A protocol with restrictive criteria often shows early signals in patient responses.
Antidote’s feasibility tests are short online surveys that put a study’s draft screening questions in front of people from the target patient population before patient recruitment begins. The results point to where screening challenges may appear.
In each case, feasibility testing gave the sponsor an opportunity to evaluate potential recruitment barriers before clinical research sites began screening.
Low enrollment is often read as low interest. Antidote’s feasibility tests show that’s not always the case. In the Parkinson’s disease test, only 9 of 214 respondents met the initial criteria, and 6 of those 9 said they were very interested in taking part.
The findings suggest that patient interest alone wasn’t the main limitation. The device-history requirement significantly reduced the number of respondents meeting the initial criteria. Without early testing, a constraint like this may only surface once clinical research sites start screening, when the cause is harder to see.
Sponsors can identify potential screening challenges by running the draft screener with the target patient population before patient recruitment begins. The results show which criteria remove the most respondents, which ones patients can’t confirm on their own and whether low numbers reflect weak interest or narrow criteria. Five steps make the findings useful.
Use the protocol’s inclusion and exclusion criteria, written in patient-friendly language, so the results reflect how the target patient population responds.
One requirement often accounts for most disqualifications. That is the criterion to discuss first with the study team.
Estimate how changing one requirement, such as a lookback window or a dose stability period, would change the qualified pool and the level of interest.
Keep criteria patients answer reliably in the online screener. For criteria patients may not answer reliably, plan an appropriate confirmation step, such as a follow-up call or a medical record review where authorized, and leave test values and imaging to the clinical research site.
Tell site coordinators which criteria may need confirmation and what screening effort to plan for, so staffing and timelines reflect the protocol they will actually run.
Site burden is the extra work clinical research sites take on to enroll each patient, such as screening patients who won’t qualify, confirming details patients couldn’t provide and following up on referrals that go nowhere.
No. A patient-facing feasibility test does not replace protocol feasibility or site selection. It reduces uncertainty about how patients will respond to the protocol and where it creates friction.
Before the protocol is finalized, when criteria can still change, or before site activation, when recruitment timelines and budgets are being set.
Antidote runs short feasibility tests that put protocol-based screening questions and draft patient-facing messages in front of relevant patient populations before patient recruitment begins. Sponsors see: